Skip to content
OpenCapital
Get started

Erasca, Inc. ERAS Acquired in-process research and development

Acquired in-process research and development at other companies

Eli Lilly logo
Eli LillyLLY
$584M-62.8%
Exelixis logo
ExelixisEXEL
$2.03M—
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s acquired in-process research and development?
Erasca, Inc. (ERAS) reported acquired in-process research and development of $150M in Q1 2026.
What does acquired in-process research and development mean?
Represents the cash consideration paid to acquire in-process research and development projects from third parties. This is a critical metric for biotech and pharmaceutical companies, indicating the level of external investment in pipeline expansion versus internal development. It reflects the company's strategy for inorganic growth and its appetite for acquiring external clinical assets.